Anti-thrombotic therapy after mitral valve surgery

Clicks: 35
ID: 323023
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #13 of 43 articles by views in european journal of cardio-thoracic surgery : official journal of the european association for cardio-thoracic surgery

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
The European and American guidelines offer recommendations for the management of antithrombotic medication following mitral valve interventions. Evidence to support recommendations is frequently extrapolated from studies of aortic valve procedures, despite thrombotic risk being substantially higher in mitral valve disease and mitral valve procedures. This review examines the pathophysiological basis for thrombosis in mitral valve conditions, the recommendations and evidence from the guidelines and current uncertainties.
Reference Key
openalex_W7171855601 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bilal H. Kirmani, A Marc Gillinov, Luke Rogers, Rebecca Maier, Raimondo Ascione, Sanjay Asopa, Enoch Akowuah
Journal european journal of cardio-thoracic surgery : official journal of the european association for cardio-thoracic surgery
Year 2026
DOI
10.1093/ejcts/ezag204
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.